Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARDX

Ardelyx, Inc.

Healthcare · Biotechnology

$3.03

Up+$0.00 (+0.00%)

Updated Nov 3, 2026, 9:25 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.59B
P/E ratio
-25.9
Dividend yield
0.00%
52-week range
$2.96 – $7.43
Volume
4.62M
Avg. volume
4.57M

Price performance · ARDX

ARDX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ARDX closed at $3.03 after 21 trading sessions, down 10.62% for the selected period.

Last close
$3.03
Period change
-10.62%
Period low
$3.00
Period high
$3.39
Daily close
View OHLC price history
ARDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$2.99$3.085$2.975$3.034.62M
Oct 30, 2026$3.09$3.119$2.96$3.033.63M
Oct 29, 2026$3.115$3.16$3.075$3.102.55M
Oct 28, 2026$2.98$3.11$2.955$3.103.94M
Oct 27, 2026$3.01$3.04$2.97$3.004.86M
Oct 26, 2026$3.08$3.11$2.99$3.005M
Oct 23, 2026$3.17$3.20$3.02$3.084.82M
Oct 22, 2026$3.13$3.22$3.11$3.202.72M
Oct 21, 2026$3.23$3.23$3.12$3.133.02M
Oct 20, 2026$3.10$3.25$3.10$3.213.96M
Oct 19, 2026$3.09$3.13$3.05$3.093.23M
Oct 16, 2026$3.26$3.265$3.08$3.095.78M
Oct 15, 2026$3.24$3.35$3.19$3.274.07M
Oct 14, 2026$3.10$3.25$3.06$3.195.83M
Oct 13, 2026$3.20$3.205$3.09$3.126.87M
Oct 12, 2026$3.28$3.28$3.18$3.233.54M
Oct 9, 2026$3.26$3.30$3.21$3.282.36M
Oct 8, 2026$3.23$3.30$3.18$3.276.54M
Oct 7, 2026$3.26$3.35$3.22$3.265.39M
Oct 6, 2026$3.39$3.4077$3.23$3.315.82M
Oct 5, 2026$3.35$3.42$3.28$3.394.25M

Latest ARDX news

The latest Smart Investors Daily articles mentioning ARDX.

Stock researchCompany · Overview

ARDX research

Overview

Company profile and research snapshot.

Company profile

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
ARDX recent ratings
DateFirmRatingTarget
Aug 19, 2026WedbushOutperform—
Aug 18, 2026WedbushOutperform—
Aug 17, 2026Piper SandlerOverweight—
Aug 10, 2026CitigroupBuy—
Aug 7, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus WALTHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signifi

Yahoo · Oct 20, 2026

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business

Yahoo · Oct 12, 2026

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of lifeWALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at th

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By